Search Results
Your search for 3 matches 14920 pages
Showing 601 - 650Advanced Melanoma: Efficacy of Monoclonal Antibody Doublet
In a phase I trial reported in the Journal of Clinical Oncology, Omid Hamid, MD, and colleagues found that the combination of the human lymphocyte activation gene-3 (LAG-3)-targeting monoclonal antibody fianlimab plus the PD-1–targeting monoclonal antibody cemiplimab-rwlc was active in patients...
Endometrial Thickness in Triage for Endometrial Cancer Among Black Women
In a study reported in JAMA Oncology, Kemi Doll, MD, MSCR, and colleagues found that ultrasonography-measured endometrial thickness was not reliable in triage for diagnosing endometrial cancer among Black women. Study Details The retrospective U.S. multicenter study focused on data from 1,494 women ...
Previously Untreated Intermediate-Risk Rhabdomyosarcoma: Addition of Temsirolimus to Chemotherapy in Young Patients
As reported in The Lancet Oncology by Gupta et al, the phase III Children’s Oncology Group ARST1431 trial showed no event-free survival benefit with the addition of temsirolimus to chemotherapy in previously untreated children, adolescents, or young adults with intermediate-risk rhabdomyosarcoma....
MAST Trial: Metformin Does Not Slow Disease Progression of Low-Risk Prostate Cancer
The hypoglycemic agent metformin failed to slow disease progression in men with low-risk localized prostate cancer undergoing active surveillance, according to the results of the randomized, controlled MAST trial reported at the 2024 ASCO Annual Meeting.1 In addition, the use of metformin was...
RELATIVITY-048: Triplet Immunotherapy Shows Activity in Untreated Advanced Melanoma
As a first-line treatment of advanced melanoma, the triplet immunotherapy regimen of nivolumab, relatlimab-rmbw, and ipilimumab produced high response rates and promising progression-free and overall survival in the nonrandomized phase I/II RELATIVITY-048 trial, as reported by Paolo Antonio...
Nonplatinum Chemotherapy Regimen for Advanced Cholangiocarcinoma
Based on the results of the multicenter phase II NIFE-AIO-YMO HEP-0315 trial, which were reported in the Journal of Clinical Oncology by Ettrich et al, first-line palliative treatment with nanoliposomal irinotecan plus fluorouracil and leucovorin appears to be safe and active in patients with...
Previously Untreated EGFR-Mutated Advanced NSCLC: Amivantamab/Lazertinib vs Osimertinib
As reported in The New England Journal of Medicine by Byoung Chul Cho, MD, PhD, and colleagues, the phase III MARIPOSA trial has shown improved progression-free survival with amivantamab-vmjw plus lazertinib vs osimertinib in previously untreated patients with EGFR-mutated advanced non–small cell...
Relapsed or Refractory Multiple Myeloma: Activity of BCMA x CD3 Bispecific Antibody
As reported in the Journal of Clinical Oncology by Bumma et al, the phase II portion of a first-in-human phase I/II trial (LINKER-MM1) showed strong activity with the B-cell maturation antigen (BCMA) x CD3 bispecific antibody linvoseltamab in patients with relapsed or refractory multiple myeloma....
Perioperative Nivolumab in Renal Cell Carcinoma
As reported in The Lancet Oncology by Allaf et al, a planned interim analysis of the phase III PROSPER ECOG-ACRIN EA8143 trial showed no recurrence-free survival benefit with perioperative nivolumab vs observation in patients undergoing nephrectomy for high-risk renal cell carcinoma. Study ...
Tai Chi vs Cognitive Behavioral Therapy: Measuring Inflammatory Biomarkers in Breast Cancer Survivors With Insomnia
Both tai chi and cognitive behavioral therapy may reduce insomnia and inflammation and bolster antiviral defenses in breast cancer survivors, according to a recent study published by Irwin et al in Brain, Behavior, and Immunity. Background Chronic insomnia—one of the most prominent symptoms...
In Gastroesophageal Cancer, ‘Switch’ Maintenance Improves Outcomes Over Chemotherapy Continuation
In patients with advanced HER2-negative gastric or gastroesophageal junction cancer and disease control after oxaliplatin-based chemotherapy, “switch” maintenance with paclitaxel plus ramucirumab in the phase III ARMANI trial significantly improved both progression-free and overall survival,...
Second-Line Therapy With Adagrasib in KRAS G12C–Mutated Non–Small Cell Lung Cancer
Second-line therapy with the KRAS inhibitor adagrasib modestly improved progression-free survival and objective response rate over docetaxel in previously treated patients with advanced KRAS G12C–mutated non–small cell lung cancer (NSCLC), according to the primary analysis of the phase III...
Neoadjuvant Combination of PD-1 and Angiogenesis Inhibitors in Genomically Unstable Colorectal Cancer: NEOCAP
As reported in The Lancet Oncology by Yu et al, based on results from the ongoing phase II NEOCAP trial, neoadjuvant therapy with the PD-1 inhibitor camrelizumab plus the angiogenesis inhibitor apatinib appears to demonstrate “promising” antitumor activity and a manageable toxicity profile in...
Adding COX-2 Inhibition to Chemotherapy in PIK3CA-Activated Stage III Colon Cancer
In an analysis from the CALGB/SWOG 80702 (Alliance) trial published by Nowak et al in the Journal of Clinical Oncology, researchers found that the addition of the cyclooxygenase 2 (COX-2) inhibitor celecoxib to standard adjuvant chemotherapy was associated with improved disease-free survival and...
FDA Grants Accelerated Approval to Epcoritamab-bysp for Relapsed or Refractory Follicular Lymphoma
On June 26, the U.S. Food and Drug Administration (FDA) granted accelerated approval to epcoritamab-bysp (Epkinly), a bispecific CD20-directed CD3 T-cell engager, for adult patients with relapsed or refractory follicular lymphoma who have received two or more lines of systemic therapy. EPCORE ...
Novel Biomarker May Be Predictive of Clear Cell Renal Cell Carcinoma Recurrence
Researchers have discovered a biomarker that could help identify which patients with clear cell renal cell carcinoma may be at greater risk of cancer recurrence, according to a recent study published by Mehra et al in JCO Precision Oncology. Background Approximately 3% to 5% of all cancer diagnoses ...
Phase III postMONARCH Trial: Switching to Abemaciclib May Improve Outcomes After Disease Progression
For hormone receptor–positive, HER2-negative advanced breast cancer that has progressed on CDK4/6 inhibition plus endocrine therapy, the CDK4/6 inhibitor abemaciclib plus fulvestrant significantly reduced the risk of further disease progression in the phase III postMONARCH study.1 “The postMONARCH ...
Recurrent or Metastatic HNSCC: First-Line VEGFR2 Plus PD-1 Inhibition
In a single-center phase I/II trial reported in The Lancet Oncology, Douglas Adkins, MD, and colleagues found that the recommended phase II dose of ramucirumab combined with pembrolizumab was active in the first-line treatment of patients with recurrent or metastatic head and neck squamous cell...
ER-Positive Advanced Breast Cancer: Oral SERD Plus Palbociclib in First-Line Setting
As reported in the Journal of Clinical Oncology by Javier Cortés, MD, PhD, and colleagues, the phase III AMEERA-5 trial of first-line treatment with the selective estrogen receptor degrader (SERD) amcenestrant plus palbociclib vs letrozole plus palbociclib in estrogen receptor (ER)-positive,...
Early Surveillance in Pediatric Patients Genetically Predisposed to Cancer
Initiating surveillance soon after recognizing a pediatric patient has a genetic predisposition for cancer may improve the identification of early-stage asymptomatic tumors, according to a recent study published by Blake et al in JAMA Oncology. The findings may inform clinical practice following...
ASCO Sets Six Guiding Principles for AI in Oncology
ASCO has released “Principles for the Responsible Use of Artificial Intelligence in Oncology,” to guide the Society’s consideration of all aspects of artificial intelligence (AI). With this manuscript, ASCO joins colleagues across medicine in offering principles that should be applied in...
ASCO Issues New Guidance on Cannabis and Cannabinoid Use in Adults With Cancer
Many Americans, including patients with cancer, use cannabis and cannabinoids. In response to this reality, ASCO has issued a guideline for clinicians, adults with cancer, caregivers, and researchers on their medical use.1 The recommendations cover all cancer types and address products ranging from ...
Long-Term Study Finds Most Breast Cancer Survivors Were Able to Preserve Fertility and Achieve Pregnancy After Diagnosis
Research examining fertility and attempts at pregnancy among young women after a breast cancer diagnosis has been hampered by short-term follow-up and a lack of prospective assessment of pregnancy attempts. However, a long-term study investigating fertility outcomes among young women who reported...
Mirvetuximab Soravtansine-gynx for FRα-Positive, Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
On March 22, 2024, mirvetuximab soravtansine-gynx (Elahere) was granted regular approval for adult patients with folate receptor–alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment...
Tovorafenib in Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma
On April 23, 2024, tovorafenib (Ojemda) was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for patients aged 6 months and older who have relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement or BRAF V600 mutation.1 Tovorafenib is a...
DREAMM-8: Belantamab Mafodotin-blmf Shows ‘Robust’ Benefit in Early Relapse of Myeloma
Recent phase III findings support the antibody-drug conjugate belantamab mafodotin-blmf as a treatment option for patients with multiple myeloma in early relapse. Belantamab mafodotin is an antibody-drug conjugate targeting B-cell maturation antigen (BCMA) expressed on multiple myeloma cells,...
Advanced Lung Cancer: Studies Explore Palliative Care Delivered by Telehealth and in a Stepped-Care Approach
Early palliative care can be integrated into the course of treatment for patients with advanced lung cancer via delivery by telehealth with outcomes similar to when palliative care is delivered via in-person visits, according to results of the REACH PC trial presented by Joseph Greer, PhD, of...
Accelerating Progress in Melanoma and Cancer Research
The Melanoma Research Alliance is on a mission to cure and prevent melanoma, a skin cancer that is diagnosed in more than 100,000 people each year and is expected to take the lives of more than 8,000 individuals in 2024.1 We invite stakeholders across all fields, including medicine, science, and...
Durvalumab Consolidation Therapy Extends Survival in Limited-Stage Small Cell Lung Cancer
Consolidation therapy with the PD-L1 antibody durvalumab after chemoradiotherapy extended survival in patients with limited-stage small cell lung cancer (SCLC) compared with standard-of-care chemoradiotherapy alone, according to the first planned interim analysis of the phase III ADRIATIC trial...
Lu-177 Dotatate for Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors
On April 23, 2024, lutetium Lu-177 dotatate (Lutathera) was approved for pediatric patients 12 years and older with somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors, including foregut, midgut, and hindgut neuroendocrine tumors.1 Lu-177 dotatate is a radiolabeled...
Addition of Adjuvant Ribociclib to Nonsteroidal Aromatase Inhibitor Therapy Improves Survival in Early Breast Cancer
As reported in The New England Journal of Medicine by Dennis Slamon, MD, PhD, of the David Geffen School of Medicine at the University of California, Los Angeles, and colleagues, interim analysis of the phase III NATALEE trial has shown improved invasive disease–free survival with the addition of...
Combination Targeted Therapy Produces Durable Responses in Patients With Relapsed DLBCL
The results from a phase Ib/II study of a five-drug regimen of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) show the treatment produced durable remissions in patients with specific molecular...
Pembrolizumab/Chemotherapy in First-Line Treatment of HER2-Negative Advanced Gastric or GEJ Adenocarcinoma
On November 16, 2023, pembrolizumab (Keytruda) was approved with fluoropyrimidine- and platinum-containing chemotherapy for first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.1 Supporting Efficacy Data Approval ...
Eflornithine for Adult and Pediatric Patients With High-Risk Neuroblastoma
On December 13, 2023, eflornithine (Iwilfin), an ornithine decarboxylase inhibitor, was approved for adult and pediatric patients with high-risk neuroblastoma with at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy.1 This represents the first...
Adjuvant Use of Alectinib in ALK-Positive NSCLC
On April 18, 2024, the ALK inhibitor alectinib was approved by the U.S. Food and Drug Administration (FDA) for adjuvant treatment after tumor resection in patients with ALK-positive non–small cell lung cancer (NSCLC), as detected by an FDA-approved test.1 Supporting Efficacy Data Approval was based ...
Immunoglobulin G Testing May Reduce Infections, Increase Receipt of Immunoglobulin Replacement Therapy in Patients With CLL and NHL
Patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) who undergo frequent immunoglobulin G testing may be less likely to experience severe infections than those who don’t undergo frequent testing, according to a recent study published by Soumerai et al in Blood Advances....
Oral SERDs Poised to Impact Treatment of Hormone Receptor–Positive Breast Cancer
Suppression of the estrogen receptor has proven to be an effective treatment for hormone receptor–positive breast cancer, but standard endocrine therapies have liabilities that are not limited to their pharmacokinetics or toxicity profiles, which allow for ligand-independent estrogen receptor...
Celecoxib May Benefit a Subset of Patients With PIK3CA Mutations
Researchers have found that administering the anti-inflammatory drug celecoxib after surgery may improve disease-free survival in a subset of patients with PIK3CA-mutated stage III colorectal cancer, according to a study published by Nowak et al in the Journal of Clinical Oncology. The findings...
Previously Untreated Advanced Clear Cell RCC: Bempegaldesleukin/Nivolumab vs TKI Therapy
As reported in the Journal of Clinical Oncology by Nizar M. Tannir, MD, FACP, and colleagues, the phase III PIVOT-09 trial has shown no objective response or overall survival benefit with bempegaldesleukin plus nivolumab vs tyrosine kinase inhibitor (TKI) treatment with sunitinib or cabozantinib in ...
Robert L. Ferris, MD, PhD, Appointed Executive Director of UNC Lineberger Comprehensive Cancer Center
Robert L. Ferris, MD, PhD, a head and neck surgical oncologist, has been named the Executive Director of the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center and UNC System Chief of Oncology Services, effective October 1, announced the Dean of the UNC School of Medicine...
Phase I Study in NHL: Use of ‘Armored’ CAR T Cells May Be Feasible After Standard CAR T-Cell Failure
A novel “armored” chimeric antigen receptor (CAR) T cell appears to be feasible for retreatment of patients with non-Hodgkin lymphoma (NHL) who fail to respond to standard CAR T-cell therapy, according to preliminary results of a phase I trial presented at the 2024 ASCO Annual Meeting.1 The unique...
Risk of Secondary Cancer After CAR T-Cell Therapy
In a single-center study reported in The New England Journal of Medicine, Hamilton et al found that second tumors had occurred in 25 of 724 patients during 15 months of follow-up after receipt of chimeric antigen receptor (CAR) T-cell therapy, including one fatal case of T-cell lymphoma. The study...
Esophageal Cancer: Neoadjuvant Triplet or Doublet Chemotherapy, With or Without Radiotherapy
As reported in The Lancet by Ken Kato, MD, and colleagues, the Japanese phase III JCOG1109 NExT trial showed that neoadjuvant triplet chemotherapy was associated with superior overall survival vs doublet chemotherapy among previously untreated patients with locally advanced esophageal squamous cell ...
Previously Untreated Metastatic Pancreatic Cancer: CD40 Agonist Plus mFOLFIRINOX
In a European phase Ib/II study (OPTIMIZE-1) reported in The Lancet Oncology, Jean-Luc Van Laethem, MD, and colleagues found that the combination of the CD40 agonist antibody mitazalimab with mFOLFIRINOX (modified fluorouracil, leucovorin, oxaliplatin, and irinotecan) showed activity in previously...
Carboplatin-Induced Nausea and Vomiting: Addition of Olanzapine to Triple Antiemetic Therapy
In a Japanese phase III trial reported in the Journal of Clinical Oncology, Inui et al found that the addition of olanzapine to triple antiemetic therapy did not improve the prevention of carboplatin-induced vomiting in patients with thoracic cancers who had received no prior chemotherapy; however, ...
Radioligand Therapy May Improve Radiographic Progression–Free Survival in Taxane-Naive Patients With Advanced Prostate Cancer
Lutetium (Lu)-177–PSMA-617 radioligand therapy may offer a statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with taxane-naive metastatic castration-resistant prostate cancer, according to findings presented by Herrmann et al at the 2024...
Efficacy of Adjuvant Everolimus Plus Endocrine Therapy in High-Risk, Hormone Receptor–Positive, HER2-Negative Breast Cancer
As reported in the Journal of Clinical Oncology by Mariana Chavez-MacGregor, MD, MSc, FASCO, and colleagues, the phase III SWOG S1207 trial showed no significant benefit in invasive disease–free survival with adjuvant endocrine therapy plus 1 year of everolimus vs 1 year of placebo in patients with ...
FDA Approves Blinatumomab as Consolidation for CD19-Positive, Ph-Negative B-Cell Precursor ALL
On June 14, 2024, the U.S. Food and Drug Administration (FDA) approved blinatumomab (Blincyto) for adult and pediatric patients aged 1 month and older with CD19-positive, Philadelphia chromosome (Ph)-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of...
FDA Approves Two Immunochemotherapy Combinations for Endometrial Cancer
On June 17, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) in combination with carboplatin and paclitaxel followed by single-agent pembrolizumab for adult patients with primary advanced or recurrent endometrial carcinoma; on June 14, the agency approved durvalumab...
Previously Treated Metastatic Colorectal Cancer: Lenvatinib/Pembrolizumab vs Standard of Care
As reported in the Journal of Clinical Oncology by Akihito Kawazoe, MD, and colleagues, the final analysis of the phase III LEAP-017 trial showed no significant overall survival benefit with lenvatinib plus pembrolizumab vs the standard of care in previously treated patients with mismatch...
